Wegovy

Andel Adds Novo's Wegovy Pill and Wegovy HD to Employer Marketplace

Image
Andel Adds Novo's Wegovy Pill and Wegovy HD to Employer Marketplace

NEW YORK – October 29, 2026 -- Andel, a direct-to-employer medication marketplace, has agreed a collaboration with Novo to offer Wegovy, including the once-daily Wegovy pill and Wegovy HD, to its employer network. Both products launched earlier in 2026.

Employers set their own contribution toward obesity treatment

Under the model, employers decide how much to contribute toward each employee's treatment. This lowers out-of-pocket costs for staff while employers keep control of spending. Andel manages the process from prescription verification to delivery through its app.

Andel pitches the offering at employers facing rising medication expenses and sells it as a route outside traditional pharmacy benefits. Large companies, small businesses and startups can all choose a contribution level that fits their budgets. Employees receive manufacturer-direct pricing across Andel's medication platform.

Novo Nordisk: Wegovy Pill Switch Study Shows 8.8 lb Loss in 3 Months

Image
Novo Nordisk: Wegovy Pill Switch Study Shows 8.8 lb Loss in 3 Months

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.

Patients switching to the oral formulation saw rapid weight-loss gains after three months

The retrospective analysis of 194 patients on the Ro telehealth platform found that 40.7% achieved weight loss of 5% or more within three months of switching from injectable semaglutide or tirzepatide to once-daily oral semaglutide (p0.001). The proportion of participants classified with a BMI of 30 kg/m2 or higher fell by 21.6 percentage points, dropping from 87.1% at baseline to 65.5% at the three-month mark.